Learning Objectives

Participants will:

 

  • Expand their knowledge on the pathology and the Molecular Landscape in BCa and its treatment consequences, including:
    • Variant (aberrant) pathologies
    • Molecular classification of BCa
    • Genomic approach in BCa.
  • Be updated on diagnostics and staging of BCa
  • Learn about NMIBC, specifically:
    • Endoscopic diagnosis and therapy
    • Treatment optimization
    • The role of local and new systemic approaches and their optimal timing
  • Learn about MIBC, specifically:
    • Surgery
      • Role of TURB in MIBC
      • Open – Robotics
      • Standardization
      • Recovery/Rehabilitation
    •  Systemic therapy (neoadjuvant and adjuvant systemic chemotherapy and immunotherapy)
    • Bladder-sparing approach
  • Be instructed on systemic therapy in metastatic bladder and urothelial cancer
  • Develop an understanding on BCa recurrence and follow-up
  • Become familiarised with the biological and therapeutic rationale behind upper tract urothelial carcinoma (UTUC)